Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study

Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study

Background: Vaccination is a promising strategy to protect vulnerable groups like inflammatory bowel disease (IBD) patients against COVID-19 and associated severe outcomes. COVID-19 vaccine clinical trials excluded IBD patients taking infliximab with azathioprine or 6-mercaptopurine (infliximab comb...

Full description

Bibliographic Details
Main Authors: Mohammad Shehab, Mohamed Abu-Farha, Fatema Alrashed, Ahmad Alfadhli, Khazna Alotaibi, Abdullah Alsahli, Thangavel Alphonse Thanaraj, Arshad Channanath, Hamad Ali, Jehad Abubaker, Fahd Almulla
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Journal of Clinical Medicine
Subjects:
immunogenicity
IBD
infliximab
azathioprine
vaccine
BNT162b2
Online Access:https://www.mdpi.com/2077-0383/10/22/5362

Internet

https://www.mdpi.com/2077-0383/10/22/5362

Similar Items